PHARMACEUTICAL COMPOSITION FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE CONTAINING PRAS40 FUSION PROTEIN

摘要

The present invention relates to a pharmaceutical composition for preventing or treating an autosomal dominant polycystic kidney disease and, more specifically, to a pharmaceutical composition for preventing or treating a polycystic kidney disease comprising, as an active ingredient, a PRAS40 fusion protein capable of penetrating into polycystic kidney disease cells.